Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
IMMP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Immutep LimitedNASDAQ: IMMP
Cash & Equivalents · Q2 FY2026 · quarter ended Dec 2025
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at A$72.75M at the end of Q2 FY2026, down 1.5% from a year earlier. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Cash & equivalents amounted to 49.4% of total assets at the end of Q2 FY2026, up 8.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -1.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
AUD · from the balance sheet
- Latest · FY2025
- 67.41M AUD
- Year-over-year change
- -58.3%
- 4-year CAGR
- +2.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 67.41M | -58.3% |
| FY2024 | 2024-06-30 | 161.79M | +31.1% |
| FY2023 | 2023-06-30 | 123.42M | +54.3% |
| FY2022 | 2022-06-30 | 80M | +33.0% |
| FY2021 | 2021-06-30 | 60.13M | — |
Cash & Equivalents vs competitors
How IMMP compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.5% is the 5th highest of 11, against a peer median of -11.2%.
- Cash & equivalents amounts to 49.4% of total assets for IMMP, versus a peer median of 80.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $194.83M USD | +111.4% | +19.6% | 96.5% | |
| Mar 2026 | $123.65M USD | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $116.64M USD | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | $105.42M USD | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Mar 2026 | $76.44M USD | +12.7% | +26.0% | 22.8% | |
| Dec 2025 | A$72.75M AUD | -1.5% | -5.5% | 49.4% | |
| Mar 2026 | $54.03M USD | -51.7% | -14.3% | 12.5% | |
| Mar 2026 | $36.22M USD | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $30.31M USD | -28.6% | -5.8% | 7.7% | |
| Mar 2026 | $28.08M USD | +115.7% | -5.4% | 84.8% | |
| Peer median (excluding IMMP) | — | -11.2% | -0.1% | 80.3% | |
Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.13M | 80M | 123.42M | 161.79M | 67.41M |
| Short-term Investments | 0 | 0 | 0 | 20.09M | 62.28M |
| Net Receivables | 6.12M | 8.37M | 7.97M | 7.56M | 7.46K |
| Inventory | (5.66M) | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.16M | 0 | 0 | 0 | 10.87M |
| Total Current Assets | 68.42M | 90.81M | 134.97M | 191.35M | 149.1M |
| Property, Plant & Equipment (Net) | 309.7K | 308.08K | 468.51K | 679.72K | 569.48K |
| Goodwill | 109.96K | 109.96K | 109.96K | 109.96K | 109.96K |
| Intangible Assets | 12.74M | 10.44M | 9.38M | 8.13M | 7.09M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 454.19K | 495.66K | 2.52M | 1.31M | 116.64K |
| Total Non-current Assets | 13.61M | 11.36M | 12.48M | 10.23M | 7.89M |
| Total Assets | 82.03M | 102.17M | 147.45M | 201.58M | 156.98M |
| Account Payables | 1.82M | 2.87M | 5.45M | 3.79M | 5.53M |
| Short-term Debt | 208.19K | 0 | 0 | 0 | 1.1M |
| Tax Payables | 0 | (32.21M) | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.75M | 3.02M | 354.84K | 428.71K | 446.95K |
| Total Current Liabilities | 5.34M | 6.41M | 9.77M | 10.49M | 12.76M |
| Long-term Debt | 2.53M | 1.45M | 835.45K | 960.76K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 811.88K | 117.25K | 164.43K | 211.02K | 274.31K |
| Total Non-current Liabilities | 3.42M | 1.68M | 1.21M | 1.57M | 589.23K |
| Total Liabilities | 8.76M | 8.09M | 10.98M | 12.06M | 13.35M |
| Common Stock | 313.42M | 367.41M | 446.27M | 542.11M | 535.07M |
| Retained Earnings | (274.64M) | (302.34M) | (339.93M) | (382.65M) | (444.08M) |
| Accumulated OCI | 34.49M | 29M | 30.13M | 30.06M | 52.65M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 73.27M | 94.08M | 136.47M | 189.52M | 143.64M |
| Total Debt | 2.82M | 1.73M | 1.23M | 1.59M | 1.63M |
| Net Debt | (57.31M) | (78.26M) | (122.19M) | (160.2M) | (65.78M) |
Immutep Limited
NASDAQ:IMMP
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.